Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and ...

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; ...

Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with ...

Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026Lead ...

Researchers at the University of Southampton have identified a new subtype of lymphoma that could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer ...

As of November 12, 2025, ProMIS has fully enrolled Cohorts 1 and 2 and is well into Cohort 3, with complete enrollment ...

Conifex Timber Inc. ('Conifex”, 'we” or 'us”) (TSX: CFF) today reported results for the third quarter ended September 30, ...

Researchers at the University of Southampton have identified a new subtype of lymphoma which could pave the way to improved and more targeted treatments for some blood cancer patients.

Detailed price information for Perion Network Ltd (PERI-Q) from The Globe and Mail including charting and trades.

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA ...

Mattr Corp. ("Mattr" or the "Company") (TSX: MATR) reported today its operational and financial results for the three and nine months ended September 30, 2025.

Armata Pharmaceuticals Announces Third Quarter 2025 Results And Provides Corporate Update. LOS ANGELES, Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (Armata or the ...